In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas

Executive Summary

Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.

You may also be interested in...



Novo-ZymoGenetics: The Next Roche-Genentech?

Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.

Co-Promotes: A Marketplace Reality, But Do They Make Sense?

Co-promotions are a hallmark of today's licensing deals as biotechs try to secure their future growth. But do they make sense--for the product, or for the partners?

Co-Promotes: A Marketplace Reality, But Do They Make Sense?

Co-promotions are a hallmark of today's licensing deals as biotechs try to secure their future growth. But do they make sense--for the product, or for the partners?

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel